Novartis thinks Arrowhead brain drug can succeed where others couldn’t

Arrowhead Inks Deal Worth Up To $2.2 Billion, Shares Jump

Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug, sending Arrowhead stock surging.

Novartis thinks Arrowhead brain drug can succeed where others couldn’t

A licensing deal worth at least $200 million will give Novartis access to a preclinical RNA medicine designed to combat diseases like Parkinson’s.

Novartis returns to alpha-synuclein with $2.2bn Arrowhead deal - Pharmaceutical Technology

Despite a trial failure in Parkinson’s disease, Novartis is having a second bite of the alpha-synuclein cherry with Arrowhead’s drug.

Arrowhead piques Novartis' neuro interest with $200M upfront deal

Arrowhead Pharmaceuticals has forged another alliance for its RNA therapies, this time collecting $200 million upfront from Novartis. The California biotech said Tuesday that the deal includes a preclinical-stage siRNA treatment ...

Arrowhead Pharmaceuticals and Novartis Join Forces on Innovative siRNA Therapy for Parkinsons Disease

' CSIMarket.com 'PASADENA, Calif. '' In an exciting development for the biotechnology landscape, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced a global licensing and collaboration agreement with Novartis aimed at advancing the treatment of synucleinopathies, particularly Parkinson's Disease.' Under this agreement, Arrowhead will license ARO-SNCA, a promising preclinical stage small interfering RNA (siRNA) therapy targeting alpha-s…